Maintenance therapy for HER2-positive advanced breast cancer
Treatments studied
Part of Cancer clinical trials.
This trial tests a combination of three drugs (pyrotinib, trastuzumab, and pertuzumab) as ongoing treatment after initial chemotherapy for HER2-positive advanced breast cancer that has not gotten worse. It aims to see if this maintenance therapy can help keep the cancer under control.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have advanced HER2-positive breast cancer (a type that has extra HER2 protein) that cannot be removed by surgery or has spread.
- You have already received 4 to 8 cycles of first-line treatment with trastuzumab, pertuzumab, and a taxane chemotherapy, and your cancer has not progressed.
- If you have brain metastases, they must be small and not causing symptoms, or you have no brain metastases at all.
- You have a good performance status (able to carry out daily activities, up to needing some help but not bedridden).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two targeted drugs (pyrotinib and trastuzumab) as maintenance therapy to keep HER2-positive breast cancer that has spread under control. It is for women who have already received some first-line treatment and are stable enough to continue therapy.
This trial tests a combination of two targeted medicines (pyrotinib and trastuzumab) with chemotherapy to treat HER2-positive advanced breast cancer that has returned or spread after stopping trastuzumab.
This trial is testing a new medicine as the first treatment for HER2-positive breast cancer that has spread or cannot be removed. It's for women who have not had chemotherapy for advanced disease.
This trial tests a combination of three drugs—pyrotinib, trastuzumab, and chemotherapy—to treat HER2-positive breast cancer that has not been treated before. HER2 is a protein found on some cancer cells; blocking it may help stop the cancer from growing.
This Phase 2 study tests whether adding trastuzumab (a targeted antibody) given with chemo and extra drugs can better treat certain HER2-positive, locally advanced or inflammatory breast cancers. It may help by improving cancer control in people who have not had prior anti-cancer treatment for their breast cancer.
This Phase 2 trial studies a second anti-HER2 treatment (given after surgery) to help lower the risk of breast cancer coming back in people with very small, node-negative, HER2-positive tumors. It will also closely monitor heart function and other side effects because these medicines can affect the body.
Hear when a new HER2-positive Breast Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.